Research programme: selective estrogen receptor modulators - Signal

Drug Profile

Research programme: selective estrogen receptor modulators - Signal

Alternative Names: CC-25493; Research programme: interleukin-6 antagonists - Signal; SP 1496; SP 263; SP 290; SP 291; SP 500263

Latest Information Update: 05 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Signal Research Division
  • Class Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Postmenopausal osteoporosis; Urinary incontinence

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top